Business context and reporting period
This is Repro-Med Systems, Inc.’s unaudited Form 10-Q for the quarter and six months ended August 31, 2013. The filing identifies the company as Repro-Med Systems, Inc., doing business as RMS Medical Products; the supplied company metadata says KORU Medical Systems, Inc. The company designs, manufactures, and markets medical devices, including the FREEDOM60 infusion pump, RMS High-Flo safety needle sets, and RES-Q-VAC suction systems.
Financial performance and position
| Metric | Three months ended August 31, 2013 | Six months ended August 31, 2013 |
|---|---|---|
| Net sales | $2.008 million, up 2.9% year over year | $3.884 million, up 5.1% |
| Gross margin | 59.8%, versus 65.9% | 61.0%, versus 64.7% |
| Operating profit | $135,572, versus $541,993 | $260,671, versus $688,114 |
| Net income | $90,709, versus $350,664 | $164,063, versus $440,983 |
| Cash from operations | Six-month inflow of $497,999, versus $377,384 | |
| Cash and cash equivalents | $1,834,566 at August 31, 2013, versus $1,930,321 at February 28, 2013 |
For the six-month period, investing activities used $154,448 and financing activities used $439,306; cash declined by $95,755. Financing outflows included repayment of $437,832 in related-party notes. At August 31, current assets were $4.458 million and current liabilities were $522,852; total liabilities were $828,028 and stockholders’ equity was $4.601 million. No note payable balances remained, though deferred capital gain and deferred tax liabilities remained.
Changes versus the prior comparable period
Sales increased, but operating profit and net income fell sharply as cost of goods sold and operating expenses rose. SG&A increased to $963,789 for the quarter and $1.915 million for six months. Management cited restricted-stock compensation amortization, expanded sales and marketing staffing, advertising and trade-show costs, and legal expenses. Cost of goods sold rose 21% in the quarter and 16% for six months; the company attributed the increase to higher sales, benefit costs, and the 2.3% medical-device excise tax. It also cited lower pricing associated with a shift toward distributors and introductory discounts as factors in lower gross margins.
Management said needle-set sales grew substantially excluding a large one-time drug-trial sale in August 2012. It also reported slower unit-volume growth, which it said may reflect reimbursement uncertainty, market saturation, and increased competition. Research and development and depreciation and amortization expenses increased year over year. Interest expense declined following debt repayment.
Outlook, risks, and unusual items
Management stated that cash and capital available at period-end, together with sales growth, should meet or exceed liquidity needs for the next twelve months. The filing provides no quantified earnings or revenue guidance and cautions that interim results are not necessarily indicative of full-year results.
Risks discussed include uncertain reimbursement and effects of health-care regulation, FDA requirements, competition, market acceptance and penetration, product development, patent protection, access to capital, and dependence on key personnel. The company had brought a declaratory judgment action concerning alleged patent infringement by its needle sets; the defendant asserted counterclaims that the company considers without merit, and counsel was reviewing them. The company also disclosed a month-to-month aircraft lease from an entity controlled by its president, with payments of $10,750 for the six months ended August 31, 2013. Management reported effective disclosure controls and no material subsequent events through October 15, 2013.
Important facts for investors to verify
- Confirm issuer identity and continuity: this filing is in the name of Repro-Med Systems, Inc., not KORU Medical Systems, Inc.
- Track whether sales growth can offset distributor-related pricing pressure, slower unit growth, and declining gross margins.
- Assess whether higher SG&A, legal, compensation, and medical-device-tax costs persist and how they affect profitability.
- Monitor reimbursement changes, competitive products, and market adoption of FREEDOM60 and High-Flo needle sets.
- Follow the patent litigation and counterclaims, and review the ongoing related-party aircraft lease.
- Evaluate liquidity and cash generation after the related-party debt repayment against management’s twelve-month liquidity expectation.